Clinical trial
A Phase Ib, Open-Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients With End-Stage Renal Disease (ESRD)
NCT02437422 is registered in ClinicalTrials.gov with Prolong Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib, Open-Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients With End-Stage Renal Disease (ESRD)
- Lead sponsor
- Prolong Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 5, 2015
- Completion date
- November 18, 2015
- Enrollment
- 5 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.